Prasugrel clinical trials
Prasugrel is named as an intervention in 7 current clinical trials in our Ireland, Spain, Poland, Netherlands, Switzerland, Norway, India, Germany, France, Italy, Belgium, Czechia, Portugal, Canada, Japan, Australia, Israel, Brazil and South Korea registers. 6 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1). The most-studied condition is Coronary Artery Disease. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Prasugrel is approved
All regulators →Of the three regulators tracked here, the first to approve Prasugrel was the EU, on 24 Feb 2009. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Prasugrel
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Prasugrel works
All drug targets →- Purinergic receptor P2Y12 antagonist AntagonistTarget: P2RY12 purinergic receptor P2Y12ChEMBL only
- COVID-19Phase 3
- Non-ST Elevation Myocardial InfarctionPhase 3
- ST Elevation Myocardial InfarctionPhase 3
- Acute chest syndromePhase 3
- Acute myocardial infarctionPhase 3
- Atrial fibrillationPhase 3
- Coronary artery disorderPhase 3
- Sickle cell diseasePhase 3
- Platelet activationPhase 2
- Platelet aggregationPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201772, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7562, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Prasugrel
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 2 technology appraisals of Prasugrel. 1 is current, and 1 of it recommends it for at least some patients. 1 older appraisal was replaced or withdrawn.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes NICE TA317 | Recommended | 23 Jul 2014 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Prasugrel
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Efient, Prasugrel Viatris (previously Prasugrel Mylan) (generic)EMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Prasugrel
- ATC code
- B01AC22
- ChEMBL
- CHEMBL1201772
- DrugBank
- DB06209
- PubChem CID
- 6918456
- CAS number
- 150322-43-3
- FDA UNII
- 34K66TBT99
- Wikidata
- Q416232
- Wikipedia
- Prasugrel
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Prasugrel
7 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Prasugrel in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Prasugrel. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
"PREVENTAMI-FX — PREvention of VENtricular Thrombosis in Acute Myocardial Infarction with FondaparinuX"
2025-524664-38-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 2 | Authorised | Azienda Unita' Sanitaria Locale Toscana Sud Est | Italy |
|
STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)
2026-525933-22-00 · Cardiovascular Diseases
|
Phase 4 | Ongoing | Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Spain, Norway |
Prasugrel across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
7 single-substance products containing Prasugrel on the HPRA medicines list.
- Prasugrel Accord 10 mg film-coated tabletsAccord Healthcare Ireland Ltd. · PA2315/157/002 · Marketed
- Efient 10 mg Film-coated tabletSubstipharm · EU/1/08/503/8-14
- Efient 5 mg Film-coated tabletSubstipharm · EU/1/08/503/1-7
- Prasugrel Viatris 10 mgMylan Pharmaceuticals Limited · EU/1/18/1273/002
- Prasugrel Viatris 5 mgMylan Pharmaceuticals Limited · EU/1/18/1273/001
Supply shortages
No entry for Prasugrel in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Prasugrel
14 conditionsAll 14 conditions
| Condition (as registered) | Trials |
|---|---|
| Coronary Artery Disease | 2 |
| Myocardial Infarction (MI) | 1 |
| Respiratory Tract Diseases | 1 |
| Influenza (Pandemic) | 1 |
| Influenza | 1 |
| Community Acquired Pneumonia | 1 |
| Coronary Arterial Disease (CAD) | 1 |
| Percutaneous Coronary Intervention (PCI) | 1 |
| Chronic Coronary Syndrome | 1 |
| Stable Coronary Artery Disease CAD | 1 |
| Percutaneous Coronary Intervention | 1 |
| Acute Coronary Syndromes | 1 |
| Antiplatelet Therapy | 1 |
| Acute Coronary Syndrome | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 1 |
| UMC Utrecht | 1 |
| J.P.S Henriques | 1 |
| Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o | 1 |
| Cardiocentro Ticino | 1 |
| Hospital Israelita Albert Einstein | 1 |
| Asan Medical Center | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Prasugrel trials
How many clinical trials are testing Prasugrel?
7 current trials in our Ireland, Spain, Poland, Netherlands, Switzerland, Norway, India, Germany, France, Italy, Belgium, Czechia, Portugal, Canada, Japan, Australia, Israel, Brazil and South Korea registers name Prasugrel as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Prasugrel trials recruiting patients?
Yes. 6 of the 7 trials are recruiting: 2 with sites in Ireland, 2 with sites in Spain, 2 with sites in Poland, 2 with sites in Netherlands, 2 with sites in Switzerland, 1 with sites in Norway, 1 with sites in India, 1 with sites in Germany, 1 with sites in France, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in Australia, 1 with sites in Israel and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Prasugrel clinical trials?
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1), UMC Utrecht (1), J.P.S Henriques (1) and Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Prasugrel clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Prasugrel licensed in Ireland?
Yes. The HPRA medicines list includes 7 single-substance products containing Prasugrel, for example Prasugrel Accord 10 mg film-coated tablets (Accord Healthcare Ireland Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Prasugrel shortage?
Not in the lists we track: Prasugrel has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prasugrel works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prasugrel works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prasugrel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.